Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Acute lymphoblastic leukaemia
Age: Adult
Dose: Intravenous – 1.4-1.5 mg/m2
Frequency: once weekly
Note: Maximum: 2 mg weekly. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration.
Indication: Acute lymphoblastic leukaemia
Age: Adult
Condition: Hepatic impairment with serum bilirubin greater than 3 mg/100ml
Dose: Intravenous – Reduce dose by 50%
Frequency: once weekly
Note: Dose adjustment may be needed for hepatic impairment. Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration.

Child Dose

Clinical InformationAdministration Information
Indication: Acute lymphoblastic leukaemia
Age: Child
Dose: Intravenous – 1.5-2 mg/m2
Frequency: once weekly
Note: Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration.
Indication: Acute lymphoblastic leukaemia
Age: Child
Dose: Intravenous – Initiate at 0.05 mg/kg
Frequency: once weekly
Note: Subsequent doses may be modified based on clinical and haematological responses and tolerance of the patient. May be used in combination with other drugs. Prescribers should consult published protocols for the dosage, method and sequence of administration.

Renal Dose

Clinical InformationAdministration Information
Condition: Renal Impairment
Dose: Dose adjustment not necessary
Note: Dosage adjustment not necessary in patients with renal impairment.
Administration
  • IV administration only
  • Must not be given intrathecally
Side Effect

Drug Interaction

Drug NameRisk Factors
Antineoplastic regimens
Decreased digoxin (tablets) and verapamil absorption
Etoposide
Increased etoposide serum levels

Disease Interaction

Disease NameRisk Factors
Charcot-Marie-Tooth Syndrome
Risk of severe neurotoxicity
Intrathecal Administration
Can be fatal

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2-8° C. Protect from light.

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.